{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:22:25Z","timestamp":1781259745631,"version":"3.54.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofdiabetes.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Diabetes"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jcjd.2021.07.004","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T11:46:11Z","timestamp":1627904771000},"page":"134-141.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A New Clinical Utility for Tubular Markers to Identify Kidney Responders to Saxagliptin Treatment in Adults With Diabetic Nephropathy"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4071-0627","authenticated-orcid":false,"given":"Marwa","family":"Mohsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0073-3066","authenticated-orcid":false,"given":"Ahmed A.","family":"Elberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa Mohamed","family":"Rabea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa Mahmoud","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed E.A.","family":"Abdelrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0503-685X","authenticated-orcid":false,"given":"Raghda R.S.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjd.2021.07.004_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/prca.201800144","article-title":"Urinary proteomics as a tool\u00a0to\u00a0identify kidney responders to dipeptidyl peptidase-4 inhibition: A hypothesis-generating analysis from the MARLINA-T2D trial","volume":"13","author":"Siwy","year":"2019","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.jcjd.2021.07.004_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1507\/endocrj.K10E-382","article-title":"Sitagliptin reduces albuminuria in patients with type 2 diabetes","volume":"58","author":"Hattori","year":"2011","journal-title":"Endocrine J"},{"key":"10.1016\/j.jcjd.2021.07.004_bib3","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.2337\/dc13-0323","article-title":"Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction","volume":"36","author":"Groop","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2021.07.004_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/dc16-0621","article-title":"Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial","volume":"40","author":"Mosenzon","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2021.07.004_bib5","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3389\/fphar.2017.00780","article-title":"Saxagliptin attenuates albuminuria by inhibiting podocyte epithelial-to-mesenchymal transition via SDF-1\u03b1 in diabetic nephropathy","volume":"8","author":"Chang","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcjd.2021.07.004_bib6","article-title":"Nephroprotection with saxagliptin [in\u00a0Italian]","volume":"32","author":"Iazzetta","year":"2015","journal-title":"G\u00a0Ital Nefrol"},{"key":"10.1016\/j.jcjd.2021.07.004_bib7","doi-asserted-by":"crossref","first-page":"7659243","DOI":"10.1155\/2018\/7659243","article-title":"Markers of glomerular and tubular damage in the early stage of kidney disease in type 2 diabetic patients","volume":"2018","author":"\u017by\u0142ka","year":"2018","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jcjd.2021.07.004_bib8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00125-014-3389-3","article-title":"Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus","volume":"58","author":"Fufaa","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.jcjd.2021.07.004_bib9","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/ki.2010.404","article-title":"Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-\u03b2-D-glucosaminidase","volume":"79","author":"Vaidya","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.jcjd.2021.07.004_bib10","article-title":"Tubulointerstitial biomarkers for diabetic nephropathy","volume":"2018","author":"Satirapoj","year":"2018","journal-title":"J\u00a0Diabetes Res"},{"key":"10.1016\/j.jcjd.2021.07.004_bib11","series-title":"Brenner and Rector\u2019s the Kidney","first-page":"1777","article-title":"Diabetic nephropathy","author":"Parving","year":"2004"},{"key":"10.1016\/j.jcjd.2021.07.004_bib12","article-title":"Clinical value of NGAL, L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients","volume":"8","author":"Chou","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jcjd.2021.07.004_bib13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000505155","article-title":"Neutrophil gelatinase-associated lipocalin and retinol-binding protein-4 as biomarkers for diabetic kidney disease","volume":"45","author":"Abbasi","year":"2020","journal-title":"Kidney Blood Pressure Res"},{"key":"10.1016\/j.jcjd.2021.07.004_bib14","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2337\/dc10-1392","article-title":"Clinical significance of urinary liver-type fatty acid\u2013binding protein in diabetic nephropathy of type 2 diabetic patients","volume":"34","author":"Kamijo-Ikemori","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2021.07.004_bib15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/14789450.2019.1659138","article-title":"Proteomics and personalized medicine: A focus on kidney disease","volume":"16","author":"Siwy","year":"2019","journal-title":"Expert Rev Proteomics"},{"key":"10.1016\/j.jcjd.2021.07.004_bib16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/jch.12586","article-title":"Inadequate blood pressure control in hypertensive patients referred for cardiac stress test","volume":"17","author":"Mousa","year":"2015","journal-title":"J\u00a0Clin Hypertens"},{"key":"10.1016\/j.jcjd.2021.07.004_bib17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.jhh.1001577","article-title":"Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension","volume":"17","author":"Chrysant","year":"2003","journal-title":"J\u00a0Human Hypertens"},{"key":"10.1016\/j.jcjd.2021.07.004_bib18","unstructured":"GraphPad. QuicCalcs. 2018. https:\/\/www.graphpad.com\/quickcalcs\/randomize1.cfm?fbclid=iwar0c9egu3ptxcwcdas_9n96a0zedif3jo1doyg8y8cdmp_apxm6ft4bdn08. Accessed April 22, 2020."},{"key":"10.1016\/j.jcjd.2021.07.004_bib19","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.numecd.2016.01.001","article-title":"Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury","volume":"26","author":"Penno","year":"2016","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.jcjd.2021.07.004_bib20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD","volume":"63","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jcjd.2021.07.004_bib21","doi-asserted-by":"crossref","first-page":"10949","DOI":"10.1038\/srep10949","article-title":"Higher plasma betatrophin\/ANGPTL8 level in type 2 diabetes subjects does not correlate with blood glucose or insulin resistance","volume":"5","author":"Abu-Farha","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcjd.2021.07.004_bib22","doi-asserted-by":"crossref","first-page":"562","DOI":"10.4103\/0253-7613.140600","article-title":"Aspirin potentiates blood glucose lowering effect of glimepiride-pioglitazone combination in streptozotocin-induced diabetic rats","volume":"46","author":"Bag","year":"2014","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.jcjd.2021.07.004_bib23","doi-asserted-by":"crossref","first-page":"e99645","DOI":"10.1371\/journal.pone.0099645","article-title":"Modification of diet in renal disease (MDRD) study and CKD epidemiology collaboration (CKD-EPI) equations for Taiwanese adults","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jcjd.2021.07.004_bib24","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jcjd.2021.07.004_bib25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1258\/0004563053857806","article-title":"An innovative Australian point-of-care model for urine albumin:creatinine ratio testing that supports diabetes management in indigenous medical services and has international application","volume":"42","author":"Shephard","year":"2005","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.jcjd.2021.07.004_bib26","first-page":"1","article-title":"Protective effect of saxagliptin against renal ischaemia reperfusion injury in rats","author":"Tekin","year":"2020","journal-title":"Arch Physiol Biochem"},{"key":"10.1016\/j.jcjd.2021.07.004_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172620","article-title":"Novel repair mechanisms in a renal ischaemia\/reperfusion model: Subsequent saxagliptin treatment modulates the pro-angiogenic GLP-1\/cAMP\/VEGF, ANP\/eNOS\/NO, SDF-1\u03b1\/CXCR4, and Kim-1\/STAT3\/HIF-1\u03b1\/VEGF\/eNOS pathways","volume":"861","author":"Kamel","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jcjd.2021.07.004_bib28","doi-asserted-by":"crossref","first-page":"e13769","DOI":"10.1111\/ijcp.13769","article-title":"Saxagliptin and vildagliptin lowered albuminuria in patients with diabetes and hypertension independent on glycaemic control","volume":"75","author":"Mohsen","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jcjd.2021.07.004_bib29","doi-asserted-by":"crossref","first-page":"104391","DOI":"10.1016\/j.phrs.2019.104391","article-title":"More than just an enzyme: dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling.","volume":"147","author":"Gupta","year":"2019","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.jcjd.2021.07.004_bib30","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2337\/db16-0796","article-title":"Proximal tubulopathy: Prime mover and key therapeutic target in diabetic kidney disease","volume":"66","author":"Gilbert","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.jcjd.2021.07.004_bib31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejphar.2016.04.005","article-title":"Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats","volume":"783","author":"Uchii","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jcjd.2021.07.004_bib32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000495517","article-title":"Amelioration\u00a0of\u00a0early markers of diabetic nephropathy by linagliptin in fructose-streptozotocin-induced type 2 diabetic rats","volume":"141","author":"Oraby","year":"2019","journal-title":"Nephron"},{"key":"10.1016\/j.jcjd.2021.07.004_bib33","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1159\/000477860","article-title":"Urinary RBP and NGAL levels are associated with nephropathy in patients with type 2 diabetes","volume":"42","author":"Wu","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.jcjd.2021.07.004_bib34","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.diabres.2014.08.026","article-title":"The changes of serum sKlotho and NGAL levels and their correlation in type 2 diabetes mellitus patients with different stages of urinary albumin","volume":"106","author":"Wu","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jcjd.2021.07.004_bib35","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/nep.12618","article-title":"Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes","volume":"21","author":"Gangadharan Komala","year":"2016","journal-title":"Nephrology"},{"key":"10.1016\/j.jcjd.2021.07.004_bib36","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.jcjd.2021.07.004_bib37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000448183","article-title":"The hyperfiltering kidney in diabetes","volume":"136","author":"Trevisan","year":"2017","journal-title":"Nephron"},{"key":"10.1016\/j.jcjd.2021.07.004_bib38","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.kint.2017.11.024","article-title":"Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development","volume":"93","author":"Nowak","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.jcjd.2021.07.004_bib39","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s10157-015-1085-3","article-title":"Novel urinary biomarkers in pre-diabetic nephropathy","volume":"19","author":"Garg","year":"2015","journal-title":"Clin Exper Nephrol"},{"key":"10.1016\/j.jcjd.2021.07.004_bib40","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/ki.2012.458","article-title":"Urine neutrophil gelatinase\u2013associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease","volume":"83","author":"Liu","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.jcjd.2021.07.004_bib41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4093\/dmj.2012.36.4.307","article-title":"Urinary neutrophil gelatinase-associated lipocalin levels in comparison with glomerular filtration rate for evaluation of renal function in patients with diabetic chronic kidney disease","volume":"36","author":"Woo","year":"2012","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.jcjd.2021.07.004_bib42","first-page":"21","article-title":"Assessment of urinary liver-type fatty acid binding protein (LFABP) levels in type 2 diabetes mellitus patients with nephropathy","volume":"13","author":"Kare","year":"2019","journal-title":"J\u00a0Clin Diagn Res"},{"key":"10.1016\/j.jcjd.2021.07.004_bib43","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2021.07.004_bib44","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2337\/dc09-0429","article-title":"Tubular and glomerular injury in diabetes and the impact of ACE inhibition","volume":"32","author":"Nielsen","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2021.07.004_bib45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/00365513.2011.645055","article-title":"The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP","volume":"72","author":"Nielsen","year":"2012","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.jcjd.2021.07.004_bib46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jcjd.2021.07.004_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-015-0025-5","article-title":"Variability in estimated glomerular filtration rate values is a risk factor in chronic kidney disease progression among patients with diabetes","volume":"16","author":"Tseng","year":"2015","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jcjd.2021.07.004_bib48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nrneph.2013.251","article-title":"The effect of RAAS blockade on the progression of diabetic nephropathy","volume":"10","author":"Roscioni","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jcjd.2021.07.004_bib49","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00125-006-0545-4","article-title":"Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure","volume":"50","author":"Nakamura","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.jcjd.2021.07.004_bib50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.diabres.2012.02.007","article-title":"Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients","volume":"97","author":"Nielsen","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jcjd.2021.07.004_bib51","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1007\/s001250050629","article-title":"Appropriate blood pressure control in NIDDM (ABCD) trial","volume":"39","author":"Schrier","year":"1996","journal-title":"Diabetologia"},{"issue":"Suppl","key":"10.1016\/j.jcjd.2021.07.004_bib52","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.amjcard.2007.03.003","article-title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: Design and methods","volume":"99","author":"Buse","year":"2007","journal-title":"Am J Cardiol"}],"container-title":["Canadian Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267121002070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267121002070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:38:01Z","timestamp":1761493081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499267121002070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1499267121002070"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjd.2021.07.004","relation":{},"ISSN":["1499-2671"],"issn-type":[{"value":"1499-2671","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A New Clinical Utility for Tubular Markers to Identify Kidney Responders to Saxagliptin Treatment in Adults With Diabetic Nephropathy","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjd.2021.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Canadian Diabetes Association.","name":"copyright","label":"Copyright"}]}}